Bozeman, Montana (December 12, 2002) - Golden Helix, Inc. (GHI) announced today they have been awarded a $750K Phase II SBIR Grant for their application: “Software Relating Genes to Disease and Clinical Outcomes.” The development of the software combines statistical theory, computer science algorithms, and genetics expertise to take advantage of the great influx of data generated by the study of the human genome, clinical trials data and the creation of inexpensive genotyping techniques. The software elucidates the complex relationship between drug efficacy, side effects, multiple interacting genes and environmental factors.
Phase I results showed it is feasible to link phenotype to genotype for a list of “candidate” genes. A novel haplotype trend test has been developed to aid in finding associations across large SNP maps. Commercialization of this technique is essential for the companies that intend to use large public or private SNP maps to locate genes that are associated with disease and drug safety and efficacy. By analyzing and interpreting clinical trial data, the software will match drugs to target populations according to their specific genotype. This enables pharmaceutical companies to create novel drugs that render maximum effectiveness and have minimum side effects, i.e. the right drug for the right person.
This new approach to pharmaceutical discovery is known as pharmacogenetics and is believed by many to be the promise of renewed growth in the pharmaceutical industry that is currently lagging behind in the number of new drugs to market and new drugs in the pipeline. With the application of genetic analysis, it is possible to save many drugs that might otherwise fail in clinical trials.
About Golden Helix, Inc.
Founded in 1998 in Bozeman, MT, Golden Helix is a leading provider of data analysis software products and services designed to accelerate life science research and increase pharmaceutical R&D productivity. The company's products enable hundreds of researchers at the world's top pharmaceutical, biotech and non-profit research organizations to discover the genes that cause disease, improve target and lead discovery processes, and advance pharmacogenetic initiatives. Its products have been cited in nearly 100 peer reviewed publications that detail ground-breaking research for discovering the genetic and environmental basis of disease and creating safer and more effective medicines.
Golden Helix is committed to Accelerating the Quest for Significance.
For more information, please visit www.goldenhelix.com.
Director of Marketing
Golden Helix, Inc.